Video

Dr. Sieber on the CHAARTED Trial

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

The study looked at patients that have received no previous treatment., Siebar says. During the trial, half the patients received standard hormonal therapy while the other half received standard hormonal therapy plus 6 cycles of docetaxel. Sieber says patients with both high-volume metastasis and low-volume disease were included in the study.

Findings over a period of years showed the survival advantage was about 17 months in the group that had high-volume metastatic disease. These results could change how patients with metastatic disease are treated initially, says Sieber. However, there is some controversy surrounding CHAARTED because the data is limited and similar studies have had differing findings.

Related Videos
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute
Manali Kamdar, MD
Ibrahim Aldoss, MD